RaySearch Laboratories AB (publ) is proud to announce that the number of radiotherapy centers in Japan that are using RayStation for treatment planning has surpassed 200. In terms of number of centers, Japan is RaySearch's second largest market.
Since the launch in 2009, RayStation has been sold to more than 900 cancer centers all over the world. The United States has the largest number of RayStation centers, with more than 250 customers. In third place, after Japan, is China, where around 80 centers have RayStation.
In 2014, the University of Tokyo Hospital was the first center to introduce RayStation in Japan. Today, 63 university hospitals and 20 advanced research institutes have adopted the software and have played a significant role in introducing the treatment planning system to the Japanese market.
During the fourth quarter of 2022, 13 new RayStation customers were added in Japan and revenues amounted to SEK 40 million. The new customers in the fourth quarter were centers with conventional linear accelerators for photon radiotherapy.
Japan is at the forefront of advanced radiotherapy techniques. In addition to treatment planning for photon and electron treatments, RayStation is also used in Japan for protons, carbon ions and BNCT (Boron Neutron Capture Therapy). RayStation's advanced functions and support for many different modalities have been a success factor in the Japanese market.
Johan Löf, founder and CEO, RaySearch, says: “Japan is an important market for RaySearch and the fact that an impressive number of Japanese radiotherapy centers have chosen RayStation as one of their tools in the fight against cancer shows that there is great confidence in our products. We are committed to continue developing innovative software for ever better and more advanced cancer treatments.”
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RayStation has been sold to over 900 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.
* Subject to regulatory clearance in some markets.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
Henrik Bergentoft, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00